Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252211948 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kimberly D Herman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Galecto Biotech AB, Cobis Science Park, Ole Maaloes Vej 3, DK-2200 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Galectin 1, Cytokines, T-Lymphocytes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galecto Biotech.
Abstract (Originalsprache)
Galectin-1 is implicated in several pro-tumourigenic mechanisms and is considered immune-suppressive. The pharmacological inhibition of galectin-1 may be beneficial in cancers in which galectin-1 is overexpressed and driving cancer progression. This study aimed to further characterise the immunosuppressive cytokines influenced by galectin-1 in in vitro immune cell cultures and an in vivo inflammatory model using a recently discovered selective inhibitor of galectin-1, GB1908. To enable a translational approach and link mouse and human pharmacology, anti-CD3/anti-CD28 stimulated T cells cultured from human whole blood and mouse spleens were compared. For in vivo studies of T cell-mediated inflammation, the concanavalin-A (Con-A) mouse model was used to induce a T lymphocyte-driven acute liver injury phenotype. The inhibition of galectin-1 with GB1908 reduced IL-17A, IFNγ and TNFα in a concentration-dependent manner in both mouse and human T cells in vitro. The immunosuppressive cytokines measured in Con-A-treated mice were all upregulated compared to naïve mice. Subsequently, mice treated with GB1908 demonstrated a significant reduction in IL-17A, IFNγ, IL-6 and TNFα compared to vehicle-treated mice. In conclusion, galectin-1 induced the production of several important immune-suppressive cytokines from T cells in vitro and in vivo. This result suggests that, in the context of cancer therapy, a selective galectin-1 could be a viable approach as a monotherapy, or in combination with chemotherapeutic agents and/or checkpoint inhibitors, to enhance the numbers and activity of cytotoxic T cells in the tumour microenvironment of high galectin-1 expressing cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Galecto Biotech AB, Cobis Science Park, Ole Maaloes Vej 3, DK-2200 Copenhagen, Denmark.
- Bioresearch and Veterinary Services, University of Edinburgh, The Chancellor's Building, 49 Little France Cresent, Edinburgh EH16 4SB, UK.
ORCID-Profile: James A Roper, Kristoffer Peterson, Robert J Slack
Förderung
- Galecto Biotech
Zitieren
APA
Herman, K. D., Holyer, I., Humphries, D. C., Adamska, A., Roper, J. A., Peterson, K., Zetterberg, F. R., Pedersen, A., MacKinnon, A. C., & Slack, R. J. (2024). Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252211948
Vancouver
Herman KD, Holyer I, Humphries DC, Adamska A, Roper JA, Peterson K, et al. Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252211948
BibTeX
@article{Herman2024,
author = {Herman, Kimberly D and Holyer, Ian and Humphries, Duncan C and Adamska, Anna and Roper, James A and Peterson, Kristoffer and Zetterberg, Fredrik R and Pedersen, Anders and MacKinnon, Alison C and Slack, Robert J},
title = {Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252211948}
}
EUVIMED